Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results

Kymera Therapeutics (NASDAQ:KYMR) released its quarterly earnings data on Thursday. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20), FiscalAI reports. The business had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%.Kymera Therapeutics’s revenue was down 60.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.88) EPS.

Here are the key takeaways from Kymera Therapeutics’ conference call:

• Kymera’s first‑in‑class oral STAT6 degrader KT‑621 showed robust STAT6 degradation, strong type‑2 biomarker suppression and dupilumab‑like clinical signals in Phase 1/1b, and is now in Phase 2b trials for atopic dermatitis (enrollment expected complete end‑2026; topline mid‑2027) and asthma (first patient dosed; data expected late‑2027).
• Kymera has initiated dosing of its oral IRF5 degrader KT‑579 in a Phase 1 SAD/MAD healthy volunteer study after IND clearance and expects first‑in‑human data in H2 2026, with a planned lupus proof‑of‑concept to follow.
• The company raised nearly $1.0 billion in 2025 and finished the year with a cash balance of $1.6 billion, which management says provides a runway into 2029 to complete KT‑621 Phase 2b trials and advance KT‑579 and other programs.
• Kymera continues partnered development with Gilead (CDK2 molecular glue) and Sanofi (IRAK4 KT‑485), with potential milestone payments (Gilead up to ~$750M; Sanofi program structure could approach ~$1B) that aren’t included in current cash guidance.
• Q4 R&D expense was $83.8 million (cash R&D ~$76.2M), a 16% increase vs. Q3, highlighting rising development spend that will drive ongoing cash burn despite the stated runway.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR traded up $4.35 during trading hours on Thursday, hitting $95.03. 1,396,717 shares of the company’s stock were exchanged, compared to its average volume of 762,639. Kymera Therapeutics has a 1-year low of $19.44 and a 1-year high of $103.00. The stock has a market capitalization of $6.84 billion, a price-to-earnings ratio of -26.47 and a beta of 2.21. The company’s 50-day moving average price is $78.37 and its 200-day moving average price is $64.89.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Royal Bank Of Canada restated an “outperform” rating and set a $108.00 price objective on shares of Kymera Therapeutics in a research note on Thursday. Truist Financial boosted their price target on shares of Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Leerink Partners upped their target price on Kymera Therapeutics from $70.00 to $118.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Barclays lifted their price objective on shares of Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 27th. Finally, Wells Fargo & Company upped their target price on Kymera Therapeutics from $69.00 to $116.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $117.60.

Insider Buying and Selling at Kymera Therapeutics

In other news, CEO Nello Mainolfi sold 100,000 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $89.17, for a total transaction of $8,917,000.00. Following the sale, the chief executive officer owned 660,482 shares of the company’s stock, valued at approximately $58,895,179.94. This trade represents a 13.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bros. Advisors Lp Baker purchased 2,005,813 shares of the stock in a transaction on Thursday, December 11th. The stock was acquired at an average cost of $86.00 per share, for a total transaction of $172,499,918.00. Following the acquisition, the director directly owned 7,955,916 shares in the company, valued at approximately $684,208,776. This trade represents a 33.71% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold a total of 450,895 shares of company stock valued at $40,486,151 in the last three months. 16.01% of the stock is owned by insiders.

Institutional Trading of Kymera Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Smartleaf Asset Management LLC boosted its stake in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC boosted its stake in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares during the last quarter. Osaic Holdings Inc. boosted its position in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Kymera Therapeutics during the 4th quarter worth about $63,000. Finally, Raymond James Financial Inc. acquired a new position in Kymera Therapeutics during the second quarter valued at approximately $73,000.

Kymera Therapeutics News Roundup

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target to $140 and reaffirmed an “overweight” rating, signaling strong analyst confidence and implying meaningful upside from current levels. Piper Sandler Raise
• Neutral Sentiment: BTIG trimmed its target slightly from $138 to $134 but kept a “buy” rating — a modest adjustment that maintains institutional support but is not a bearish signal. BTIG Note
• Negative Sentiment: Kymera reported Q4 EPS of ($0.97), missing consensus (loss of $0.77) and posted revenue of $2.87M versus estimates near $14.8M; revenue fell ~60.8% year‑over‑year — a material earnings and top-line miss that increases short-term execution risk. Q4 Results
• Negative Sentiment: CEO Nello Mainolfi sold 30,000 shares for ~$2.71M (filed with the SEC). Insider sales can be interpreted negatively by some investors even though the CEO retains a large stake. Insider Sale
• Neutral Sentiment: Technical/contextual note: the stock is trading well above its 50‑ and 200‑day moving averages and near its 52‑week high, reflecting strong momentum that may amplify both positive analyst headlines and headline-driven volatility.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.